Meloxicam as an adjuvant to peginterferon‐α‐2a and ribavirin treatment for genotype 1 chronic hepatitis C: A randomized trial

Abstract

Meloxicam enhanced antiviral efficacy and reduced the decline in neutrophil counts for the peginterferon and ribavirin treatment of genotype 1 chronic hepatitis C. This drug could be a reasonable adjuvant for the treatment of patients with chronic hepatitis C. The present study including a small number of patients warrants larger clinical trials.